里昂发表研究报告，在原厂药和慢性病药的带动下，预期京东健康第三季药物销售保持稳健的按年逾30%增长，而保健品则维持按年增长逾20%，因此预计第三季总收入按年增25%至166亿元，经调整Ebit或按年升逾40%至12亿元。至于下半年的展望，该行则预计收入将按年升20%，意味着第四季按年升幅为16%。该行上调2025年全年收入增幅预测至22%，料Ebit利润率为5.7%(原预测5.0%)，上调公司今明两年的经调整净利润预测5%和4%，目标价由64港元上调至66港元，重申“跑赢大市”评级。
里昂发表研究报告，在原厂药和慢性病药的带动下，预期京东健康第三季药物销售保持稳健的按年逾30%增长，而保健品则维持按年增长逾20%，因此预计第三季总收入按年增25%至166亿元，经调整Ebit或按年升逾40%至12亿元。至于下半年的展望，该行则预计收入将按年升20%，意味着第四季按年升幅为16%。该行上调2025年全年收入增幅预测至22%，料Ebit利润率为5.7%(原预测5.0%)，上调公司今明两年的经调整净利润预测5%和4%，目标价由64港元上调至66港元，重申“跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.